2025 has been a pivotal year for biosimilars. New regulatory expectations, stronger analytical frameworks, and a renewed emphasis on lifecycle monitoring have pushed developers closer than ever to one key…
In 2025, the life sciences industry faces a paradox.We have more powerful biological tools than ever before yet the margin for analytical error has never been smaller. Small errors, subtle…
Biosimilars are no longer an emerging segment they are becoming a central pillar of global healthcare. As patents on biologics expire, biosimilars promise affordability, wider access, and large-scale impact in…
As gene and cell therapies (GCTs) take center stage in modern medicine, the spotlight is often on innovation — editing genes, engineering cells, designing CAR-T, or tailoring stem-cell therapies. But…
When it comes to immunoassays whether for biomarker discovery, diagnostic development, or translational research — the devil is often in the details.And one of the most important, yet under-appreciated details,…
Immunology is evolving faster than ever, from breakthroughs in T-cell biology to next-generation immunodiagnostics and host-pathogen insights. But behind every great discovery lies something fundamental: Reliable reagents.Reproducible workflows.Tools built with…
In the last decade, immunology has evolved from a niche discipline to the very foundation of modern medicine. From checkpoint inhibitors and CAR-T therapy to mRNA vaccines and rapid immunodiagnostics,…
The hidden variable behind every reliable result? In every lab, there is one constant truth, your results are only as reliable as the conditions you create. While researchers spend countless…
The enzyme-linked immunosorbent assay (ELISA) remains a cornerstone technique in bioanalytical testing. From assessing pharmacokinetics and immunogenicity in biopharma to serving as the analytical backbone for many diagnostic assays, ELISA…
Meeting EMA & FDA Guidelines Introduction — why robust HCP detection matters now Biologic drugs and biosimilars depend on consistent, safe manufacturing. When E. coli is used as the expression…
When a diagnostic kit reaches a clinician or a point-of-care test station, the end user expects one thing above all: consistent, trustworthy results. For antigen-detection tests — especially for high-impact targets…
Introduction In the complex world of biopharma, diagnostics and clinical research, one process quietly drives accuracy and trust:bioanalytical method development. Whether it’s quantifying therapeutic antibodies, detecting biomarkers, or validating immunoassays, the enzyme-linked…
